Clinical trials: Ischemic Brain
Acute Ischemic Stroke
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke
- Trial name
- NCT07754825
- Testing
- LT3001 Drug:high dose, LT3001 Drug: low dose
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
The objective of the study is to evaluate the safety and effectiveness of the Route 92 Medical Monopoint Reperfusion System with the Hi Point 88 and HiPoint 70 Reperfusion Catheters when used to aspirate emboli in acute ischemic…
- Trial name
- SUMMITNZ (NCT05429658)
- Testing
- Thrombectomy
- Where
- 2 sites in New Zealand
- Volunteers
- 66 people
- Sponsor
- Route 92 Medical, Inc.
Acute Ischemic Stroke, Intracranial Stenosis
Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)
Study objective is to evaluate the efficacy and safety of acute permanent stenting of symptomatic intracranial stenosis following unsuccessful recanalization by thrombectomy in acute ischemic stroke with large vessel occlusion…
- Trial name
- ACUTE (NCT03955835)
- Testing
- Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
- Where
- 8 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Acandis GmbH
Cadasil
Efficacy and Safety of Tocotrienols in CADASIL
CADASIL is a paradigmatic cerebral small vessel disease responsible for white-matter lesions, accumulation of lacunes, microbleeds and cerebral atrophy.
- Trial name
- NCT04658823
- Testing
- HOV-12020 (Palm tocotrienols complex)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hovid Berhad
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd
Cerebral Infarction
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.
- Trial name
- NCT03176498
- Testing
- Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Cerebral Infarction
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.
- Trial name
- NCT00272454
- Testing
- Cilostazol, Aspirin
- Where
- 12 sites in South Korea
- Volunteers
- 468 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Ischemic Stroke
Safety and Performance Evaluation of the Magneto Wire
A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Wire in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.
- Trial name
- NCT03890380
- Testing
- Magneto Wire
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Magneto Thrombectomy Solutions
Ischemic Stroke
Cerebrolysin REGistry Study in Stroke
Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.
- Trial name
- CREGS-S (NCT02541227)
- Testing
- Cerebrolysin
- Where
- Austria
- Volunteers
- 1,823 people
- Sponsor
- Ever Neuro Pharma GmbH
Ischemic Stroke
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- RODIN (NCT05041010)
- Testing
- Neu2000KWL group
- Where
- 24 sites in South Korea
- Volunteers
- 496 people
- Sponsor
- GNT Pharma
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Cerebral Ischemia, Cerebral Infarction
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with…
- Conditions
- Cerebral Ischemia, Cerebral Infarction, Stroke, Acute
- Trial name
- NCT04047563
- Testing
- Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
- Where
- 11 sites in India
- Volunteers
- 158 people
- Sponsor
- Pharmazz, Inc.
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
- Trial name
- NCT06380699
- Testing
- QHRD106 Injection, Human Urinary Kallidinogenase
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Acute Ischemic Stroke, Large Vessel Occlusion
Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke
The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.
- Trial name
- ARTEMIS (NCT07174505)
- Testing
- Mechanical Thrombectomy using the CONDA Stent Retriever
- Where
- 2 sites in Hungary, Spain
- Volunteers
- 50 people
- Sponsor
- Anaconda Biomed S.L.
Stroke
Desmoteplase in Acute Ischemic Stroke (DIAS)
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after…
- Trial name
- NCT00638781
- Testing
- Desmoteplase
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- PAION Deutschland GmbH
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05445895
- Testing
- Renexin CR 200/160mg, Plavix 75mg
- Where
- South Korea
- Volunteers
- 483 people
- Sponsor
- SK Chemicals Co., Ltd.
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cardiovascular Disease
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
- Trial name
- CARES (NCT01101035)
- Testing
- Febuxostat, Allopurinol
- Where
- 203 sites in United States, Mexico
- Volunteers
- 6,198 people
- Sponsor
- Takeda